Peer review reports
From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
| Original Submission |
| 26 Apr 2016 |
Submitted |
Original manuscript
|
|
Author responded |
Author comments
|
|
Reviewed |
Reviewer Report
|
| Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
|
Author responded |
Author comments
|
| Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
|
Author responded |
Author comments
|
| Resubmission - Version 4 |
|
Submitted |
Manuscript version 4
|
| Publishing |
| 27 Jul 2016 |
Editorially accepted |
|
| 4 Aug 2016 |
Article published |
10.1186/s12885-016-2633-2
|
Learn about peer review
